Biogen Announces Move to New Headquarters in Kendall Common

The Cambridge-based biotech will consolidate operations into a sustainable 580,000-square-foot facility set to open in 2028.

Biogen's new headquarters at 75 Broadway will be the first private development in MIT's Kendall Common project, a 10-acre mixed-use innovation hub.
The facility will integrate Biogen's research, development, and commercialization teams to enhance collaboration and innovation.
This move aligns with Biogen's cost-cutting initiatives, reducing its local office footprint by 412,000 square feet across three buildings.
The building, jointly developed by MIT and BioMed Realty, will feature advanced sustainable design and conservation elements.
Scheduled to open in 2028, the move coincides with Biogen's 50th anniversary, reinforcing its commitment to the Massachusetts life sciences ecosystem.